Edition:
United Kingdom

China Regenerative Medicine International Ltd (8158.HK)

8158.HK on Hong Kong Stock

0.08HKD
8:59am BST
Change (% chg)

HK$-0.00 (-5.00%)
Prev Close
HK$0.08
Open
HK$0.08
Day's High
HK$0.08
Day's Low
HK$0.08
Volume
9,640,000
Avg. Vol
12,502,047
52-wk High
HK$0.24
52-wk Low
HK$0.08

Summary

Name Age Since Current Position

Xuejun Wang

51 2018 Chief Executive Officer, Executive Director

Chi Hung Mui

50 2016 Chief Financial Officer

Xiaohu Sun

54 2018 Chief Operating Officer

Jinnan Zhang

33 2018 Chief Technology Officer

Ray Yip

67 2018 Compliance Officer, Chief Medicine Officer, Executive Director

Yong Shan

42 2018 Vice President

Wing Hang Chan

2015 Group Financial Controller

Chengyu Xiong

63 2018 Chief Development Strategy Officer

Chai Fu Cheng

2016 Company Secretary

Bing Woon Chan

69 2014 Independent Non-Executive Director

Jun Fang

55 2017 Non-Executive Independent Director

Yiu Kit Wong

2017 Independent Non-Executive Director

Biographies

Name Description

Xuejun Wang

Mr. Wang Xuejun is Chief Executive Officer, Executive Director of the Company. is a master of business administration from Nankai University. He was an executive deputy general manager of Vcanbio Cell & Gene Engineering Corp., Ltd. (stock code on the Shanghai Stock Exchange: SH600645), general manager of marketing center of Union Stemcell & Gene Engineering Co., Ltd and head of its subsidiary, and a director and general manager of certain subsidiaries of Heze Biotech Co., Ltd. He was also a director and general manager of Heze Biotech Co., Ltd. and a doctor at Tianjin Rehabilitation Center.

Chi Hung Mui

Mr. Mui Chi Hung serves as Chief Financial Officer of the Company. He has over 20 years of experience in financing, auditing and accounting. Prior to joining the Company, Mr. Mui held various senior positions in a few listed groups and international accounting firm, including PricewaterhouseCoopers, Lansen Pharmaceutical Holdings Limited (stock code: 503) (“Lansen”), China Smarter Energy Group Holdings Limited (formerly known as “Rising Development Holdings Limited” (stock code: 1004) (“Rising”)) and Legend Strategy International Holdings Group Company Limited (stock code: 1355). He spent 7 years serving as the Financial Controller, Company Secretary and Executive Director in Rising and 5 years serving as the Chief Financial Officer and Company Secretary in Lansen. Mr. Mui obtained his bachelor’s degree in Management majoring in Accounting from the University of Lethbridge in Canada and his master’s degree in Professional Accounting from the Hong Kong Polytechnic University. Mr. Mui is currently a member of AICPA and HKICPA.

Xiaohu Sun

Dr. Sun Xiaohu is Chief Operating Officer of the Company. He is a doctor of medicine (immunology) from Shanghai Jiao Tong University School of Medicine and holds an EMBA degree from Shanghai Jiao Tong University. Dr. Sun has 36 years’ experience in listed biotechnology companies, pharmaceutical companies, medical enterprises, research institutes and hospitals; and 18 years’ experience as chief executive officers and senior executives in domestic and international pharmaceutical and medical device companies. He is a senior professional manager with good medical education background. Dr. Sun was the operation director and marketing director of VCANBIO; the general manager of Shanghai Claison Bio-tech Co., Ltd; the general manager of Shanghai Donghai Pharmaceutical Co., Ltd and its three branches; the marketing director of Heho Biotech (Shanghai) Co., Ltd.* under Morningside Group; the assistant group general manager of Vitop Bioenergy (China) Limited general manager of its Shanghai company; the director of East China office of Tat Lung Medical Treatment Technology Limited, Hong Kong; the vice president of marketing of Shenzhen Biological Valley Technology Investment Co., Ltd; and the administrative physician/assistant to department director of Qingdao University Medical College.

Jinnan Zhang

Dr. Zhang Jinnan is Chief Technology Officer of the Company. He holds D.Phil degree in Engineering Science of Oxford University. Dr. Zhang was postdoctoral research assistant in Institute of Biomedical Engineering, Oxford University, assistant to CEO of the Company, and deputy general manager of Shenzhen Ainear Cornea Engineering Co., Ltd

Ray Yip

Dr. Ray Yip is Compliance Officer, Chief Medicine Officer, Executive Director of the Company. DrHe is also a member of the remuneration committee of the Company. Dr. Yip joined the Group in February 2017 as a nonexecutive Director. He had been re-designated as an executive Director in September 2017. He is an international public health leader who has made a significant contribution to global health in the areas of nutrition, maternal and child health, HIV/AIDS and tobacco control. Dr. Yip has been working on emergency response to war and famine, long term program and policy development effort in the PRC in recent years. Dr. Yip was the founding director of the Chinese office of U.S. Centers for Disease Control and Prevention (the “CDC”) in 2013, and the China program director of the Bill and Melinda Gates Foundation (the “Foundation”) in 2017. Dr. Yip is known as a specialist for health and medical issues in the PRC. Dr. Yip graduated from the Medical School and the School of Public Health of the University of Minnesota, and he was then certified as a pediatric hematologistoncologist.

Yong Shan

Mr. Shan Yong is Vice President of the Company. He holds a bachelor’s degree in economics from Northwest A&F University. He worked at a well-known major enterprise group in the PRC from 2000 to 2013, serving as the South China regional general manager of the group. He invested in a well-known insurance company in 2003 and was involved in its management, where he was involved in the launch of the first Chinese-US joint venture fund management company in the PRC. He took overall responsibility for investment, financing, operation and management in the South China region in 2005. He invested in the construction of a large-scale industrial base of the group in that region in 2006. He acquired the first largescale Chinese-foreign cooperative medical institution in Shenzhen, the PRC, in 2008 and served as the dean of the institution, with overall responsibility for the construction, management and operation of the project. He served as a council member of the Red Cross Society of China Shenzhen Branch in 2011. Since 2013, he has been involved in the launch of a private fund management company in Shenzhen, which invests in the military, cultural and other industries.

Wing Hang Chan

Mr. Chan Wing Hang, CPA, is Group Financial Controller of China Bio-Med Regeneration Technology Limited. Mr. Chan joined the Group in August 2011. He obtained Bachelor Degree in Business Administration (Honors) in Accountancy from City University of Hong Kong and was graduated from University of Hull in January 2012 with Master Degree in Business Management. Mr. Chan is a fellow member of the Association of Chartered Certified Accountants and a member of the Hong Kong Institute of Certified Public Accountants. He is currently the chief financial officer and company secretary of Sijia Group Company Limited (the shares of which are listed on the Main Board of the Stock Exchange, stock code: 1863), in which he is responsible for the overall financial control, company secretarial, compliance and investor relation functions. Mr. Chan had served as the financial controller, qualified accountant and company secretary of China National Materials Company Limited (the shares of which are listed on the Main Board of the Stock Exchange, stock code: 1893). He was the vice financial controller, qualified accountant and company secretary of Western Mining Company Limited (the shares of which are listed on The Shanghai Stock Exchange, stock code: 601168), and the qualified accountant and company secretary of Shinhint Acoustic Link Holdings Limited (the shares of which are listed on the Main Board of the Stock Exchange, stock code: 2728). Mr. Chan has more than 14 years of experience in accounting, finance, compliance, company secretarial, investor relations and initial public offerings.

Chengyu Xiong

Prof. Dr. Xiong Chengyu is Chief Development Strategy Officer of the Company. He is currently a professor and a doctoral supervisor of the School of Journalism and Communication of Tsinghua University in China. Professor Xiong has extensive experience in new media studies, media development and journalism. He was a member of each of the Advisory Committee for State Informatisation* and the Advisory Committee for Internet Development and Management, and served as a vice dean of the School of Journalism and Communication of Tsinghua University in China. Professor Xiong currently serves as a member of the University Academic Committee and the chairman of the National Research Center of Cultural Industries in Tsinghua University in China. Professor Xiong was an independent director of each of Hunan TV & Broadcast Intermediary Co., Ltd (Shenzhen Stock Exchange: 000917) and China South Publishing & Media Group Co., Ltd.* (Shanghai Stock Exchange: 601098). He currently serves as an independent director of Jiangsu Broadcasting Cable Information Network Corporation Limited* (Shanghai Stock Exchange: 600959).

Chai Fu Cheng

Mr. Cheng Chai Fu is Company Secretary of the Company. Mr. Cheng graduated from Victoria University of Wellington, New Zealand with a bachelor degree of commerce and administration and obtained a Master of Business Administration from Murray State University, Kentucky of the United States of America. He is an associate member of The Hong Kong Institute of Chartered Secretaries with extensive experience in the areas of auditing, accounting and company secretarial work.

Bing Woon Chan

Mr. Chan Bing Woon is Independent Non-Executive Director of China Bio-Med Regeneration Technology Limited. Mr. Chan joined the Group in March 2014. Mr. Chan is a consultant of Yung, Yu, Yuen & Co., Solicitors and Notaries. He has about 39 years experience in the legal profession. Mr. Chan has been involved in numerous public duties including being Advisor of the Joint Mediation Helpline Office. He is also a fellow member of the Hong Kong Institute of Directors, a council member of the Hong Kong Society of Notaries, a member of the Hospital Authority and a general accredited mediator of Hong Kong International Arbitration Centre and the Law of Society of Hong Kong. Mr. Chan was also a past Chairman of the Hong Kong Mediation Council. He is currently an independent non-executive director of Kwoon Chung Bus Holdings Limited (the shares of which are listed on the Main Board of the Stock Exchange, stock code: 306).

Jun Fang

Dr. Fang Jun is Non-Executive Independent Director of the Company. He served as an executive member and the executive vice-chairman of the Cross-straits Medicine Exchange Association of the National Health and Family Planning Commission of the PRC, an executive member and the vice-chairman of China Sexology Association, the publisher and the executive chief editor of the China Sexology Journal and the deputy head of the Sexology Research Center of Peking University Health Science Center. Dr. Fang also assumed various positions such as the executive member and the secretary general of Wu Jieping Medical Foundation. Dr. Fang graduated from Peking University Health Science Center with a master’s degree in Social Medicine and Health Service Management and a doctorate degree in Epidemiology and Health Statistics. Dr. Fang is also an independent non-executive director of HongDa Financial Holding Limited, a company listed on the Stock Exchange (1822.HK).

Yiu Kit Wong

Mr. Wong Yiu Kit Ernest is an Independent Non-Executive Director of the Company. He has over 25 years of experience in venture capital, corporate finance, business development and general management. Mr. Wong has served as the president and group chief financial officer of KVB Kunlun Holdings Limited (“KVB”) since November 2011 and as the chief financial officer and the company secretary of KVB’s group company, KVB Kunlun Financial Group Limited, the shares of which are listed on The Stock Exchange of Hong Kong Limited (the “Stock Exchange”) (HKEx stock code: 8077) since October 2014. Mr. Wong has also served as an independent non-executive director of Renheng Enterprise Holdings Limited (HKEx stock code: 3628) since October 2011, HongDa Financial Holding Limited (HKEx stock code: 1822) since July 2014, Legend Strategy International Holdings Group Company Limited (HKEx stock code: 1355) since November 2016 and Progressive Path Group Holdings Limited (HKEx stock code: 1581) since November 2016. Mr. Wong also served several positions at Adamas Finance Asia Limited (LSE stock code: ADAM), including its executive director from May 2008 to February 2014, its chief financial officer from May 2008 to October 2011 and its non-executive director since February 2014. Mr. Wong obtained a bachelor’s degree in business administration from The University of Hong Kong in 1991, a master’s degree of science in investment management from The Hong Kong University of Science and Technology in 1998 and a master’s degree of science in electronic engineering from The Chinese University of Hong Kong in 2008.